

## *CURRICULUM VITAE*

### **Roger L. White, PharmD, FCCP**

Work Address: QF 219, 280 Calhoun St  
College of Pharmacy  
PO Box 250142  
Medical University of South Carolina  
Charleston, South Carolina 29425

Office phone: (843) 792-8462  
Fax: (843) 792-1712  
E mail: whiterl@musc.edu

#### **ACADEMIC APPOINTMENTS**

July 1998 - present: Professor, College of Pharmacy, Medical University of South Carolina, Charleston, SC

July 2000 - July 2001 Acting Chair, Department of Pharmaceutical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC

April 1991 - June 1998: Associate Professor, College of Pharmacy, Medical University of South Carolina, Charleston, SC

October 1994 - present: Member, Graduate Faculty, Medical University of South Carolina Charleston, SC

August 1985 - March 1991: Assistant Professor, College of Pharmacy, Medical University of South Carolina Charleston, SC

July 1983 - July 1985: Assistant Clinical Professor of Pharmacy, University of Connecticut Storrs, Connecticut

#### **EDUCATIONAL BACKGROUND**

##### **Doctor of Pharmacy, 1983**

Medical College of Virginia/Virginia Commonwealth University

##### **B.S. Pharmacy, 1979**

University of North Carolina at Chapel Hill

#### **FELLOWSHIP**

July 1983 - July 1985: **Clinical Pharmacy Fellowship (Infectious Disease)**  
Hartford Hospital, Hartford, Connecticut  
Preceptors: Charles H. Nightingale, Ph.D. and Richard Quintiliani, M.D.

## **PUBLICATIONS**

White RL, Enzweiler, KA, Friedrich LV, Wagner D, Hoban D, , JA. Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of *Streptococcus pneumoniae* in the United States during 1999-2000. *Diagn Microbiol Infect Dis* (in press).

Bonapace CR, White RL, Friedrich LV, Bosso JA. Differences in antimicrobial drug exposure in patients with varying degrees of renal function based upon recommendations from dosing references. *Pharmacotherapy* (in press)

White RL, Antibiotic resistance: where do the ketolides fit? *Pharmacotherapy* 2002;22(1 Pt 2):18S-29S

Kays, MB, White, RL, Friedrich, LV. Effect of Serum from Different Patient Populations on the Serum Bactericidal Test. *J Antimicrob Chemother.* 2001;48(9):417-420.

Hodges B and White RL. Antimicrobial cycling: the future or just a fad? *Annals of Pharmacotherapy.* 2001;35(10):1224-1232.

White RL. What in-vitro models of infection can and cannot do. *Pharmacotherapy* 2001;21(11 Pt 2):292S-301S.

White RL, Friedrich LV, Burgess DS, Brown EW, Scott LE. Effect of removing duplicate isolates on cumulative susceptibility reports. *Diagnostic Microbiology and Infectious Disease.* 2001.39:251-256..

White RL, Friedrich LV, Manduru M, Mihm L, Bosso J. Comparative in vitro pharmacodynamics of imipenem and meropenem against *Esherichia coli*, *Staphylococcus aureus*, and *Bacteroides fragilis* . *Diagnostic Microbiology and Infectious Disease* 2001 39:39-47.

White RL, Friedrich LV, Mihm L, Bosso J. Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient care areas. *Clinical Infectious Diseases* 2000; 31(1):16-23.

Bonapace CR, White RL, Friedrich LV, Bosso JA. Evaluation of antibiotic synergy against *Acinetobacter baumannii*: A comparison with E-test, time-kill, and checkerboard methods. *Diagnostic Microbiology and Infectious Disease* 2000; 38:43-50.

Bonapace CR, White RL, Friedrich LV, Norcross ED, Bosso JA. Pharmacokinetics of cefepime in patients with thermal injury. *Antimicrobial Agents and Chemotherapy* 1999;43:2848-2854

Bosso JA, Bonapace CR, Flume PA, White RL. A pilot study of the efficacy of constant infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. *Pharmacotherapy* 1999;19:620-626.

Friedrich LV, White RL, Bosso J. Impact of multiple antimicrobial usage on changes in susceptibility of Gram-negative aerobes. *Clin Infect Dis.* 1999;28:1017-24.

White RL, Burgess DS, Friedrich LV, Walker MA, Bosso JA. Comparison of various susceptibility testing methods of  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations based upon predicted in vivo serum concentrations. *J Infect Dis Pharmacother* 1998.3(1):13-26.

Manduru M, Mihm LM, White RL, Friedrich LV, Flume PA, Bosso JA. Comparative bactericidal activity of ceftazidime against isolates of *Pseudomonas aeruginosa* as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method. *Antimicrob Agents Chemother* 1997; 41(11):2527-2532.

Manduru M, Mihm LM, White RL, Friedrich LV, Flume PA, Bosso JA. In vitro pharmacodynamics of ceftazidime against *Pseudomonas aeruginosa* isolates derived from cystic fibrosis patients. *Antimicrob Agents Chemother.* 1997;41(9):2053-6.

Manduru M, Mihm LM, White RL, Friedrich LV, Bosso JA. A new in vitro model for the assessment of antimicrobial pharmacodynamics; description and assessment of performance characteristics. *J Infect Dis Pharmacother.* 1997; 2(3):29-46.

Markowitz JS and White RL. Pharmacists as laboratory-based researchers. *J Pharm Prac.* 1997; 9(6):467-470.

Burgess DS, White RL, Friedman R, Bosso JA. Impact of different methodologies on the estimation of antibiotic tissue penetration: determination of cefmetazole penetration into bone and soft tissue *J Infect Dis Pharmacother.* 1996; 2(1):15-28.

Voit EO, Berg PH, White, RL. A pharmacodynamic model for the action of the antibiotic imipenem on *P. aeruginosa* populations in vitro. *Bull Math Biol.* 1996;58(5):923-938.

White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. *Antimicrob Agents Chemother.* 1996; 40(8): 1914-18.

White RL, Friedrich LV, Burgess DS, Warkentin DI, Bosso JA. Comparative in vitro pharmacodynamics of imipenem and meropenem against *P. aeruginosa*. *Antimicrob Agents Chemother.* 1996; 40(4):904-8.

Bosso JA, Taylor AJ, White RL, Sabados BK. Compatibility of two concentrations of recombinant human interleukin-1 receptor antagonist with selected antimicrobial agents. *J Infect Dis Pharmacother* 1996;1:45-54.

Friedrich LV, White RL, Burgess DS, Warkentin DI, Bosso JA. Comparative stability of imipenem and meropenem in Mueller-Hinton broth at room temperature, during incubation, and during frozen storage. *J Infect Dis Pharmacother* 1995; 1(2): 21-34.

Friedrich LV, White RL, Kays MB, Burgess DS. Drug degradation during HPLC analysis of aztreonam: Effect on pharmacokinetic parameter estimation. *Annals Pharmacother* 1994; 28: 444-6.

Nicolau DP, White RL, Friedrich LV, Kays MB. Antibiotics: A descriptive and economic evaluation of parenteral usage in a burn unit. *Journal of Burn Care and Rehabilitation*, May 1993.

White RL, Kays MB, Friedrich LV, Del Bene VE. Impact of different statistical methodologies on the in-vitro microbiologic evaluation of selected cephalosporin/cephamycins against *Bacteroides fragilis*. *J Antimicrob Chemother* 1993; 31:57-64.

White RL, Burgess DS, Friedrich LV. Analysis of multiple antimicrobial usage on changes in susceptibility of gram-negative aerobes. *Hospital Formulary Highlights of the ACCP Annual Meeting, January 1993 (page 2).*

Kays MB, White RL, Gatti G, Gambertoglio JG. Ex vivo protein binding of clindamycin in sera with normal and elevated  $\alpha_1$ -acid glycoprotein concentrations. *Pharmacotherapy* 1992; 12(1):50-55).

Friedrich LV, White RL, Kays MB, Burgess DS. Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma. *Am J Hosp Pharm* 1992; 49:590-594.

White RL, Kays MB, Friedrich LV, Koonce JR. External factors affecting imipenem performance in dried microdilution MIC plates. (Author's reply) *J Clin Microbiol* 1992; 30(2):535-536.

Kays MB, White RL, Friedrich LV, Del Bene VE. Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties. *Clin Ther* 1991; 13(5):596-605.

Uber WE, Brundage RC, White RL, Brundage DM, Bromley HR. In vivo inactivation of tobramycin by piperacillin. *DICP, Ann Pharmacother* 1991; 25:357-359.

White RL, Kays MB, Friedrich LV, Brown EW, Koonce JR. Pseudoresistance of *Pseudomonas aeruginosa* resulting from degradation of imipenem in an automated susceptibility testing system with predried panels. *Journal of Clinical Microbiology* 1991; 29(2):398-400.

Friedrich LV, White RL, Brundage DM, Kays MB, Friedman RJ. Effect of tourniquet inflation on cefazolin tissue penetration. *Pharmacotherapy* 1990; 10(6):373-377.

Friedrich LV, White RL, Kays MB, Brundage DM, Yarbrough DM. Pharmacokinetic evaluation of aztreonam in burn patients. *Antimicrob Agents Chemother.* 1991; 35(1):57-61.

Friedman RJ, Friedrich LV, White RL, Kays MB, Brundage DM, Graham J. Antibiotic prophylaxis and tourniquet inflation in total knee arthroplasty. *Clinical Orthopedics and Related Research* 1990;260:17-23.

Friedrich LV, White RL, Reboli A. Pharmacodynamics of trimethoprim-sulfamethoxazole in *Listeria meningitis*: a case report. *Pharmacotherapy* 1990;10(4):301-304.

White RL, Kays MB, Armstrong TA, Friedrich LV. The effect of supraphysiologic temperature and serum dilution on protein binding. *Antimicrob Agents Chemother.* 1990;34(6):1257-1258.

White RL, Nightingale CH, Quintiliani R. Serum and uterine tissue concentrations of cefoxitin and cefotaxime in women undergoing hysterectomy. *Drugs.* 1988;35 (Suppl. 2):72-77.

Baron KA and White RL. Antibiotic Efficacy Review. *Pharmacy Practice News*, Sept. 1987; pp. 19-30.

Marchbanks CR, Yost RL, White RL. Cefotaxime stability during in vitro microbiological testing. *Antimicrob Agents and Chemother.* 1987; 31(9):1375-1378.

White RL, Nightingale CH, Quintiliani R. Imipenem/cilastatin: a cost effective therapeutic alternative. *Infections in Medicine* 1985; July-August: 209-214.

Rosenfeld B, Quintiliani R, Klimek JJ, White RL, Nightingale CH, and Bartlett RS. Clinical and microbiological evaluation of fosmidomycin in the treatment of infections caused by *Pseudomonas aeruginosa*. *Curr Ther Res* 1985; 3(37): 458-464.

White RL, Garnett WR, Allen JR, et al. Phenytoin removal during plasma exchange. *J Clin Apheresis* 1987; 3(3): 147-150.

White RL, Garnett WR, Poynor WJ, et al. Removal of salicylate during plasma exchange in normal volunteers. *Clin Pharm* 1984; 3: 396-402.

White RL. Trimethoprim/Sulfamethoxazole: Update after a decade of use. *Hartford Hospital Drug Information Newsletter.* Jan-Feb 1984.

## **ABSTRACTS**

Enzweiler KA, Lorenz KR, Bosso JA, White RL. Decreasing susceptibility to fluoroquinolones over time: differences in geographic areas. *Pharmacotherapy* 2001;21:1274.

Enzweiler KA, Bosso JA, White RL. Comparative carbapenems pharmacodynamics against common Gram-positive and Gram-negative organisms. *Pharmacotherapy* 2001;21:1274.

Enzweiler KA, Lorenz KR, Bosso JA, White RL. Worldwide trends in carbapenems susceptibility patterns, 1985-2000. *Pharmacotherapy* 2001;21:1274.

Enzweiler K, Lorenz K, Bosso J, White R. Comparative fluoroquinolone pharmacodynamics against common Gram positive and Gram negative organisms over a range of creatinine clearance. *Proceedings of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy*, p 28 Abstract #A-2072.

White R, Enzweiler K, Friedrich L, Lorenz K, Voit E, Bosso J. Monte Carlo analysis of levofloxacin and gatifloxacin pharmacodynamics using expected dosing in a patient population with varying degrees of renal function

in 4,738 recent clinical isolates of *Streptococcus pneumoniae*. Proceedings of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p 28 Abstract #A-2073.

White R, Friedrich L, Enzweiler K, Lorenz K, Bosso J, Wagner D. Assessment of the potential for city-wide antibiograms: differences in in vitro activity against *Streptococcus pneumoniae* within major metropolitan areas in the United States. Proceedings of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p 143 Abstract #C2-2110.

Enzweiler K, Lorenz K, Bosso J, White R. Agreement among different markers of antibiotic use over and eight year period. Proceedings of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p 410 Abstract #K-1199.

White RL, Enzweiler KA, Bosso JA. Evaluation of variability in MIC<sub>90</sub> values for single vs multi-center trials. *Pharmacotherapy* 2002;22:412.

Enzweiler KE, Lorenz KR, Bosso JA, White RL. Comparative variability in MIC<sub>90</sub> values from single vs. multicenter trials. Proceedings of the 101<sup>st</sup> American Society for Microbiology General Meeting, p. 135 Abstract A-87, 2001.

Enzweiler KE, Lorenz KR, Bosso JA, White RL. Relationships between antibiotic use and the rates of isolation and antibiotic susceptibility of Gram-positive bacteria. *Pharmacotherapy* 2001;21:375-6.

Bonapace CR, Lorenz KR, Bosso JA, White RL. Effect of impaired renal function on flouroquinolone pharmacodynamics against streptococci. *Pharmacotherapy* 2000;20:1252.

Bonapace CR, Lorenz KR, Fowler JG, Bosso JA, White RL. Quantitative assessment of relationships between antibiotic use and susceptibility of Gram-negative aerobes over an 8-year period. *Pharmacotherapy* 2000;20:1252.

Bonapace CR, Lorenz KR, Bosso JA, White RL. Organism and drug specific variability in the MIC<sub>50</sub> and MIC<sub>90</sub> values of fluorquinolones. Proceedings of the 100<sup>th</sup> American Society for Microbiology General Meeting, p. 23 Abstract #A91, 2000.

Bonapace CR, White RL, Friedrich LV, Bosso JA. Differences in fluoroquinolone MICs between Europe and North American against 16 bacterial species. Proceedings of the 100<sup>th</sup> American Society for Microbiology General Meeting, p. 201 Abstract #C301, 2000.

Bonapace CR, Lorenz KR, Bosso JA, White RL. Use of different measures of drug usage in assessing antibiotic use/susceptibility relationships. Proceedings of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.403 Abstract #98, 2000.

Bonapace CR, Lorenz KR, Bosso JA, White RL. Quantitation of increasing resistance to fluoroquinolones in N. America, Europe, and Asia, 1982-2000. Proceedings of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.403 Abstract #99, 2000.

Bonapace CR, Lorenz KR, Fowler JA, Bosso JA, White RL. Differences in fluoroquinolone pharmacodynamics against recent isolates of 20 different bacterial species. Proceedings of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.9 Abstract #297, 2000.

Bonapace CR, Lorenz KR, Bosso JA, White RL. Cost of therapy with fluoroquinolones in patient populations with various distributions of renal function. Proceedings of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.504 Abstract #118, 2000.

Bonapace CR, Lorenz KR, Bosso JA, White RL. Effect of impaired renal function on flouroquinolone pharmacodynamics against streptococci. Proceeding of the Annual Meeting of the American College of Clinical Pharmacy, p. 516, Abstract #139, 2000

Bonapace CR, Lorenz KR, Bosso JA, White RL Evaluation of factors influencing the estimation of creatinine

clearance in burn patients. ACCP Spring Practice and Research Forum. April 5, 2000 and *Pharmacotherapy* 2000; 20(34): 1-2.

Bonapace CR, Friedrich LV, White RL, Bosso JA. Determination of antibiotic effect in an in vitro model: Comparison with an established animal model. Proceedings of the 39<sup>th</sup> Interscience Conference of Antimicrobial Agents and Chemotherapy, p.26 Abstract #A998, 1999 and Encore presentation at ACCP Annual Meeting

Bonapace CR, White RL, Lorenz KR, Bosso JA. Worldwide trends in fluoroquinolone susceptibility patterns, 1983-1999. Proceedings of the 39<sup>th</sup> Interscience Conference of Antimicrobial Agents and Chemotherapy, p.180 Abstract #C2261, 1999 and Encore presentation at ACCP Annual Meeting.

Bonapace CR, White RL, Friedrich LV, Bosso JA. Comparison of methods of interpretation with checkerboard synergy testing against 10 clinical isolates of *Acinetobacter baumannii*. Proceedings of the 99<sup>th</sup> American Society for Microbiology General Meeting, p. 18 Abstract #A87, 1999.

Bonapace CR, White RL, Friedrich LV, Bosso JA. Impact of differences in dosing recommendations among antimicrobial dosing references on pharmacodynamic parameters. *Pharmacotherapy* 1998;18(5):1151. (Encore at ACCP Annual Meeting)

Bosso JA, Bonapace CR, White RL, Friedrich LV, Cappelletty DM, Mercier RC, Houlihan HH, Aeschlimann JR, Rybak MJ. Differences in antimicrobial effect determined with three in-vitro pharmacodynamic models. Proceedings of the 38<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.42 Abstract #A134, 1998 and Encore presentation at 1998 ACCP Annual Meeting, *Pharmacotherapy* 1998;18(5):1151.

Bonapace CR, White RL, Friedrich LV, Bosso JA. Variability in antimicrobial dosing and pharmacodynamic profiles based on recommendations among standard clinical references. Proceedings of the 38<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 33 Abstract #A105, 1998.

Bonapace CR, White RL, Friedrich LV, Mihm LB, Bosso JA. Comparative activity of trovafloxacin and tobramycin, in combination with piperacillin and cefepime against clinical isolates of *Acinetobacter baumannii* assessed by three different methods. Proceedings of the 98<sup>th</sup> American Society for Microbiology General Meeting, p. 41 Abstract #A20,1998 and Encore presentation at 1999 ACCP Annual Meeting. *Pharmacotherapy* 1999;19(10):1209.

Bonapace CR, Friedrich LV, White RL, Norcross ED, Mihm LB, Bosso JA. Pharmacokinetics of cefepime in patients with thermal injury. *Pharmacotherapy* 1998;18(2):439.

Bonapace CR, Friedrich LV, White RL, and Bosso JA. Determination of antibiotic effect in an in-vitro model: comparison with an established animal model. Proceeding of the 34<sup>rd</sup> Annual Medical University of South Carolina Student Research Day 1999, Abstract #68, 1999.

Bonapace CR, White RL, Lorenz KR, Diep L, Bosso JA. Methodological issues of comparing fluoroquinolone pharmacodynamics against common pathogens. American College of Clinical Pharmacy 1999 Annual Meeting Infectious Diseases PRN, 1999.

Bonapace CR, White RL, Lorenz KR, Diep L, Bosso JA. Comparative fluoroquinolone pharmacodynamics against common pathogens. *Pharmacotherapy* 1999;19(10):1206.

Bonapace CR, White RL, Bosso JA. Differences in fluoroquinolone pharmacodynamic profiles against common pathogens. *Pharmacotherapy* 1999;19(4):488.

Bonapace CR, Flume PA, White RL, Bossa JA. Comparative efficacy of continuous infusion ceftazidime in adults with cystic fibrosis. *Pharmacotherapy* 1998;18(5):1164.

Bonapace CR, Flume PA, White RL, Bossa JA. Comparative efficacy of continuous infusion ceftazidime in adults with cystic fibrosis. Proceeding of the 33<sup>rd</sup> Annual Medical University of South Carolina Student Research Day 1998, Abstract #91, 1998.

Bonapace CR, White RL, Friedrich LV, Bosso JA. Evaluation of changes in susceptibility of Gram-negative aerobes: Pitfalls in examining single drug relationships. Proceeding of the 32<sup>nd</sup> Annual Medical University of South Carolina Student Research Day 1997, Abstract # 6, 1997.

Bonapace CR, White RL, Friedrich LV, Bosso JA. Comparative efficacy of continuous infusion ceftazidime in adults with cystic fibrosis. American College of Clinical Pharmacy Annual Meeting. Cincinnati, Ohio. November 11, 1998

Bosso JA, Bonapace C, White R, Friedrich LV, Cappelletty D, Mercier R, Houlihan H, Aeschlimann JR, and Rybak M. Differences in antimicrobial effect determined with three in vitro pharmacokinetic models. American College of Clinical Pharmacy Annual Meeting. Cincinnati, Ohio. November 11, 1998 (Encore)

Bonapace CR, White RL, Friedrich LV, Bosso JA. Impact of differences in dosing recommendations among antimicrobial dosing references on pharmacodynamic parameters. American College of Clinical Pharmacy Annual Meeting. Cincinnati, Ohio. November 11, 1998 (Encore)

Bosso JA, Bonapace C, White R, Friedrich LV, Cappelletty D, Mercier R, Houlihan H, Aeschlimann JR, and Rybak M. Differences in antimicrobial effect determined with three in vitro pharmacokinetic models. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California. September 27, 1998.

Bosso JA, Bonapace CR, Friedrich LV, and White RL. Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection. Society of Infectious Diseases Pharmacists Annual Meeting. September 24, 1998.

Bonapace CR, White RL, Friedrich LV, Bosso JA. Variability in antimicrobial dosing and pharmacodynamic profiles based on recommendations from standard clinical references. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California. September 27, 1998.

Bonapace CR, White RL, Friedrich LV, Mihm LB, Bosso JA. Comparative activity of trovafloxacin and tobramycin in combination with piperacillin and cefepime against clinical isolates of *Acinetobacter baumannii* assessed by three different methods. 98th General Meeting of the American Society for Microbiology. Atlanta, Georgia. May 19, 1998.

Bonapace CR, Friedrich LV, White RL, Mihm LB, Bosso JA. Pharmacokinetics of cefepime in patients with thermal injury. American College of Clinical Pharmacy Winter Practice and Research Forum. Palm Springs, California. April 6, 1998. (#77)

Sartoris KE, White RL, Lawrence B, Brown E, Byrne TK, Norcross DE, Adams D. Development and evaluation of a risk assessment index for early presumptive antifungal therapy in a surgical intensive care unit. American College of Clinical Pharmacy Practice and Research Forum. April 7, 1998

White RL, Friedrich LV, Yarbrough D, Rinaldi MG. Alterations of fluconazole pharmacokinetics in severely burned patients. American College of Clinical Pharmacy Annual Meeting. Phoenix, Arizona. November 11, 1997 (Abstract #11 Encore).

Mihm LB, White RL, Friedrich LV, Bosso JA. Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient care areas. 18th Annual Meeting of the American College of Clinical Pharmacy. Phoenix, Arizona. November 11, 1997. (#297)

Mihm LB, White RL, Friedrich LV. Reevaluation of susceptibility breakpoints of fluoroquinolones based on pharmacodynamic parameters. American College of Clinical Pharmacy Annual Meeting. Phoenix, Arizona. November 11, 1997 (Abstract #110).

Mihm LB, Friedrich LV, White RL, Bosso JA. Comparative pharmacodynamics of levofloxacin, ofloxacin, and

ciprofloxacin against common nosocomial pathogens. American College of Clinical Pharmacy Annual Meeting. Phoenix, Arizona. November 11, 1997. (Abstract #109 Encore)

White RL, Kennedy, MJ, Mihm LB, Friedrich LV. Variability in antimicrobial dosing recommendations among standard clinical references. American College of Clinical Pharmacy Annual Meeting. Phoenix, Arizona. November 11, 1997. (Abstract #108)

White RL, Friedrich LV, Mihm LB, Bosso JA. Evaluation of changes in susceptibility of gram-negative aerobes: pitfalls in examining only single drug relationships. American College of Clinical Pharmacy Annual Meeting. Phoenix, Arizona. November 11, 1997. (Abstract #75 Encore)

Bonapace C, White RL, Friedrich LV, Mihm LB, Bosso JA. Evaluation of changes in susceptibility of gram-negative aerobes: pitfalls in examining only single drug relationships. Student Research Day, Medical University of South Carolina, Charleston, South Carolina. November 7, 1997.

White RL, Friedrich LV, Yarbrough D, Rinaldi MG. Alterations of fluconazole pharmacokinetics in severely burned patients. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. October 1, 1997. (Abstract #A-89)

White RL, Friedrich LV, Mihm LB, Bosso JA. Evaluation of changes in susceptibility of gram-negative aerobes: pitfalls in examining only single drug relationships. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. September 28, 1997. (Abstract #C-26)

Mihm LB, Friedrich LV, White RL, Manduru M, Bosso JA. Comparative pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin against common nosocomial pathogens. 97th General Meeting of the American Society for Microbiology. Miami Beach, Florida. May 8, 1997. (Abstract #A-152)

Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. Concentration-dependent bactericidal activity of constant infusion ceftazidime in cystic fibrosis-derived *Pseudomonas aeruginosa* in an in vitro pharmacodynamic model. 10th Annual North American Cystic Fibrosis Conference. *Pediatr Pulmonol* 1996;(Suppl 13):293.

White RL, Manduru M, Mihm L, Friedrich LV, Bosso JA. Assessment of pharmacodynamic ratios associated with maximal bactericidal activity with imipenem and meropenem. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. September 16, 1996. (Abstract #A45)

Manduru M, White RL, Friedrich LV, Mihm L, Flume P, Bosso JA. Evaluation of differences in concentration dependent bactericidal activity in cystic fibrosis-derived *Pseudomonas aeruginosa* in an in vitro model. 17th Annual Meeting of the American College of Clinical Pharmacy. Nashville, Tennessee. August 6, 1996.

Manduru M, White RL, Friedrich LV, Mihm L, Flume P, Bosso JA. Differences in concentration-dependent bactericidal activity among *P. aeruginosa* isolates from cystic fibrosis patients. 1996 Winter Practice and Research Forum of the American College of Clinical Pharmacy. Monterey, California. February 13, 1995. (Abstract #47)

Manduru M, Fariello A, White RL, Bosso JA. Compatibility and stability of admixtures of ceftazidime sodium and teicoplanin in peritoneal dialysis solution. 30th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 6, 1995. (Abstract #P 278-E)

White RL, Manduru M, Friedrich LV, Bosso JA. Comparative in vitro pharmacodynamics of imipenem and meropenem during time-kill testing. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California. (Abstract #1658)

White RL, Burgess DS, Manduru M, Bosso JA. Comparison of an Epsilometer Test (E Test) method of antimicrobial synergy testing with checkerboard and time-kill methods. 16th Annual Meeting of the American College of Clinical Pharmacy. Washington, DC, August 9, 1995. (Abstract #109 Encore).

White RL, Burgess DS, Manduru M, Friedrich LV, Bosso, JA. Comparison of in vitro activity of antimicrobial

combinations utilizing an area under the kill curve technique. 19th International Congress of Chemotherapy. Montreal, Canada, July 20, 1995. (Abstract #4234)

White RL, Burgess DS, Prevost-Smith E, Steed L. Evaluation of the Difco ESP blood culture system in antimicrobial susceptibility testing. 19th International Congress of Chemotherapy. Montreal, Canada, July 20, 1995. (Abstract #4233)

White RL, Burgess DS, Manduru M, Bosso JB. Comparison of an epsilometer test method of antimicrobial synergy testing with checkerboard and time-kill methods. 95th American Society for Microbiology Annual Meeting. Washington, D.C., May 24, 1995. (Abstract #C343)

Bosso JA, Taylor AJ, Sabados K, White RL, Jacobson T, Chang B. Compatibility of interleukin-1 receptor antagonist (rhIL-1ra) with various antibiotics under simulated Y-site conditions. 1995 Winter Practice and Research Forum of the American College of Clinical Pharmacy. Orlando, Florida, February 14, 1995. (Abstract #48)

White RL, Burgess DS, Bosso JA. Comparative pharmacodynamic analysis of oral beta-lactams. 1995 Winter Practice and Research Forum of the American College of Clinical Pharmacy. Orlando, Florida, February 14, 1995. (Abstract #39)

White RL, Burgess DS, Friedrich LV. Comparative pharmacokinetics of cefazolin and cefmetazole during prophylaxis for total knee arthroplasty. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, Florida, October 5, 1994. (Abstract #A21)

Burgess DS, White RL, Bosso JA. Effect of intracellular fluid (ICF) dilution on estimates of cefmetazole tissue concentrations. 15th Annual Meeting of the American College of Clinical Pharmacy. St. Louis, Missouri, August 2, 1994. (Abstract #109)

White RL, Burgess DS, Friedrich LV. Contrasting effects of intrinsic antimicrobial activity of serum and ultrafiltrate on gram-positive cocci versus gram-negative bacilli. 94th Annual Meeting of the American Society for Microbiology. Las Vegas, Nevada, May 25, 1994. (Abstract #C324)

White RL, Burgess DS, Friedrich LV, Groke C. Differences in susceptibility among intensive care units and comparison to hospital-wide susceptibility patterns. 1994 American College of Clinical Pharmacy Winter Practice and Research Forum. San Diego, California, February 8, 1994. (Abstract #37)

White RL, Burgess DS, Bosso JA, Walker M. Comparison of susceptibility testing methods of beta-lactam/beta-lactamase inhibitor combinations based on human pharmacokinetics. 14th Annual Meeting of the American College of Clinical Pharmacy. Reno, Nevada, August 17, 1993. (Abstract #74)

White RL, Burgess DS, Friedrich LV, Kays MB, Warkentin DI. Concentration dependent activity of imipenem and meropenem during time-kill testing. 14th Annual Meeting of the American College of Clinical Pharmacy. Reno, Nevada, August 17, 1993. (Abstract #80 Encore)

Burgess DS, White RL, Friedrich LV. Evaluation of serum concentration/MIC relationships with parenteral beta-lactams. 14th Annual Meeting of the American College of Clinical Pharmacy. Reno, Nevada, August 17, 1993. (Abstract #71)

White RL. Intrinsic activity of human serum against gram-negative bacteria. 18th International Congress of Chemotherapy, Stockholm, Sweden, June 29, 1993. (Abstract #P065)

White RL, Friedrich LV, Burgess DS, Kays MB. Time-dependent differences in the relationship between antimicrobial usage and changes in susceptibility. 93rd General Meeting of the American Society for Microbiology, May 18-20, 1993, Atlanta, Georgia. (Abstract #C-187)

Burgess DS, White RL, Friedrich LV. Differences in susceptibility of variants of the same species from the same culture site. 93rd General Meeting of the American Society for Microbiology. Atlanta, Georgia, May 18, 1993. (Abstract #C-189)

White RL, Friedrich LV, Burgess DS. Use of pharmacodynamic data to establish initial antimicrobial breakpoint concentrations. 93rd General Meeting of the American Society for Microbiology. Atlanta, Georgia, May 18, 1993. (Abstract #C-192)

Burgess DS, White RL, Friedrich LV, Kays MB. Evaluation of antimicrobial breakpoints (BP) based on pharmacodynamic (PD) relationships. 1993 Winter Practice and Research Forum of the American College of Clinical Pharmacy, Ft. Lauderdale, Florida, February 9, 1993. (Abstract #54)

White RL, Burgess DS, Friedrich LV, Kays MB, Warkentin DI. Potential impact of degradation imipenem vs. meropenem on in vitro susceptibility. 1993 Winter Practice and Research Forum of the American College of Clinical Pharmacy, Ft. Lauderdale, Florida, February 9, 1993. (Abstract #55 Encore)

Burgess D, White R, Friedrich L, Kays M. Evaluation of antimicrobial breakpoints based on pharmacodynamic relationships. Student Research Day, Medical University of South Carolina, Charleston, South Carolina, November 6, 1992.

White RL, Burgess DS, Friedrich LV, Kays MB, Warkentin DI. Potential impact of degradation of imipenem vs. meropenem on in vitro susceptibility. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, California. October 12, 1992. (Abstract #117)

White RL, Burgess DS, Friedrich LV, Kays MB, Warkentin DI. Concentration dependent activity of imipenem and meropenem during time-kill testing. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, California. October 14, 1992. (Abstract #1613)

White RL, Burgess DS, Friedrich LV. Analysis of multiple antimicrobial usage on changes in susceptibility of gram-negative aerobes. 13th Annual Meeting of the American College of Clinical Pharmacy. Toronto, Ontario, Canada. August 10, 1992. (Abstract #55)

White RL, Friedrich LV, Burgess DS. Effect of Mueller-Hinton broth and zinc supplementation on the activity of imipenem and meropenem. 1992 American Society of Microbiology General Meeting. New Orleans, Louisiana. May, 1992. (Abstract #C-249)

White RL, Friedrich LV, Kays MB. Differential effect of serum on the susceptibility of Gram-positive and Gram-negative organisms. American College of Clinical Pharmacy Winter Practice and Research Forum. Phoenix, Arizona. February 9-12, 1992. (Abstract #57 Encore)

Warkentin DI, White RL, Friedrich LV, Kays MB. Indicators of antibiotic usage in a university hospital. The 26th Annual American Society of Hospital Pharmacists Midyear Clinical Meeting. New Orleans, Louisiana. December 10, 1991. (Abstract #97R)

White R, Friedrich L, Kays M, Zahaykevich A, Koonce J. Protein binding of azithromycin in sera with normal and elevated alpha-1 acid glycoprotein. The 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois. September 30, 1991. (Abstract #132)

White RL, Friedrich LV, Kays MB, Brown EW, Scott LE. Duplicate isolates: evaluation of their effect on antibiogram susceptibility reports. The 12th Annual Meeting of the American College of Clinical Pharmacy. Minneapolis, Minnesota. August 20, 1991. (Abstract #29 Encore)

Friedrich LV, White RL, Kays MB. Degradation during HPLC analysis: Effect on pharmacokinetic parameter estimation. The 12th Annual Meeting of the American College of Clinical Pharmacy. Minneapolis, Minnesota. August 20, 1991. (Abstract #69)

White RL, Friedrich LV, Kays MB, Brown EW, Scott LE. Use of susceptibility ratios as a marker of changes in susceptibility in individual patients. The 17th International Congress of Chemotherapy. Berlin, Germany. June 26, 1991. (Abstract #1432)

White RL, Kays MB, and Friedrich LV. Effect of heat-inactivation of serum on antimicrobial activity. The 17th International Congress of Chemotherapy. Berlin, Germany. June 25, 1991. (Abstract #653)

White RL, Kays MB and Friedrich LV. Effect of media and drug degradation during in vitro testing on the activity of imipenem. 1991 ASM Annual Meeting. Dallas, Texas. May 5-9, 1991.

White RL, Friedrich LV, Kays MB, Brown EW, and Scott LE. Effect of removal of duplicate isolates on antimicrobial susceptibility reports. 1991 ASM Annual Meeting. Dallas, Texas. May 5-9, 1991.

Friedrich LV, White RL, Kays MB, Burgess D. Pharmacoeconomic evaluation of penetrating abdominal trauma. American College of Clinical Pharmacy Winter Practice and Research Forum. Ft. Lauderdale, Florida. February 11, 1991.

Kays MB, White RL, Friedrich LV, Del Bene VE. Pharmacodynamic evaluation of cephalosporins with anti-anaerobic activity. American College of Clinical Pharmacy Winter Practice and Research Forum. Ft. Lauderdale, Florida. February 11, 1991.

White RL (Contributor) A comparison of cefprozil to cefaclor for the treatment of pharyngitis and tonsillitis. Bristol-Myers Squibb Pharmaceutical Research Institute. The 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia. October 23, 1990. (Abstract #1328).

White RL (Contributor) Safety and efficacy of cefprozil compared to cefaclor in the treatment of mild to moderate skin and skin structure infections. Bristol-Myers Squibb Pharmaceutical Research Institute. The 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia. October 23, 1990. (Abstract #630).

White RL, Kays MB, Friedrich LV, Brown EW. "Pseudo" resistance of pseudomonas-degradation of imipenem in susceptibility panels. 11th Annual Meeting of the American College of Clinical Pharmacy. San Francisco, California. August 6, 1990. (Abstract #9).

Friedrich LV, White RL, Kays MB, Brundage DM, Yarbrough DM. Pharmacokinetic evaluation of aztreonam in burn patients. 11th Annual Meeting of the American College of Clinical Pharmacy. San Francisco, California. August 7, 1990. (Abstract #64).

White RL, Kays MB, Del Bene VE, Friedrich LV. Effect of descriptive statistics on the analysis of cephalosporin activity against *B. fragilis*. International Congress for Infectious Diseases. Montreal, Canada. July 19, 1990. (Abstract #331).

White RL, Kays MB, Friedrich LV, Brown EW. Antimicrobial degradation in an automated susceptibility testing system. Sixth International Congress on Rapid Methods and Automation in Microbiology and Immunology. Helsinki, Finland. June 9, 1990. (Abstract #374).

White RL, Brown EW, Friedrich LV, Kays MB. Effect of Age of Breakpoint Panels on Imipenem Susceptibility Patterns. 90th Annual Meeting of the American Society for Microbiology. Anaheim, California. May 15, 1990. (Abstract #C-269).

White RL, Kays MB, Armstrong TA, Friedrich LV. Effect of Heat-inactivation and Serum Dilution on Protein Binding. 90th Annual Meeting of the American Society for Microbiology. Anaheim, California. May 15, 1990. (Abstract #C-268).

Nicolau DP, White RL, Friedrich LV, Kays MB. The Impact of the Antibiotic Order Form on Antibiotic Use in the Burn Treatment Center. 24th Annual ASHP Midyear Clinical Meeting. Atlanta, Georgia. December 3-7, 1989. (Abstract #P-345R).

Uber WE, Kays MB, Friedrich LV, White RL. Acinetobacter: An Emerging Pathogen. 24th Annual ASHP Midyear Clinical Meeting. Atlanta, Georgia. December 3-7, 1989. (Abstract #P-319R).

White RL, Kays MB, Friedrich LV, Brundage RC. Variability in the Relationship Between Antibiotic Breakpoints

and Achievable Serum Concentrations. 10th Annual Meeting, American College of Clinical Pharmacy. Kansas City, Missouri. August 9, 1989. (Abstract #98).

Kays MB, White RL. Effect of Elevated Alpha-1 Acid Glycoprotein Concentration on the Serum Protein Binding of Clindamycin. 10th Annual Meeting, American College of Clinical Pharmacy. Kansas City, Missouri. August 9, 1989. (Abstract #96).

Friedrich LV, White RL, Brundage DM. The Effect of the Time of Tourniquet Inflation on Cefazolin Disposition During Knee Arthroplasty. 10th Annual Meeting, American College of Clinical Pharmacy. Kansas City, Missouri. August 9, 1989. (Abstract #97).

Friedrich LV, White R, Brundage D. Evaluation of antibiotic costs as related to DRG reimbursement for nosocomial pneumonia. 46th Annual Meeting, American Society of Hospital Pharmacists. Nashville, Tennessee. June 7, 1989. (Abstract #69-R).

White RL, Friedrich LV, Kays MB, Brundage DM. Disproportionate Changes in Vancomycin and Nafcillin Usage Based on Susceptibility Patterns. 89th Annual Meeting, American Society for Microbiology. New Orleans, LA. May 18, 1989. (Abstract #2069).

White RL, Friedrich LV, Kays MB. Reevaluation of Aminoglycoside Breakpoints Based on Pharmacodynamic Relationships. 89th Annual Meeting, American Society for Microbiology. New Orleans, LA. May 18, 1989. (Abstract #2071).

Kays MB, White RL. Comparison of Serum Bactericidal Activity Between Different Patient Populations. 89th Annual Meeting, American Society for Microbiology. New Orleans, LA. May 15, 1989. (Abstract #2070).

Hogan K, White R, Gudeman S, Henderson F. Vancomycin Pharmacokinetic and Pharmacodynamic Parameters in Patients with Cerebrospinal Fluid Shunt Infections. 90th Annual American Society for Clinical Pharmacology and Therapeutics. Nashville, Tennessee. March 10, 1989.

Hogan K, White R, Gudeman S, Henderson F. Serum and Cerebrospinal Fluid Concentrations of Cefotaxime and Desacetylcefotaxime in Patients With CSF Shunt Infections. 90th Annual American Society for Clinical Pharmacology and Therapeutics. Nashville, Tennessee. March 10, 1989.

Friedrich LV, Brundage DM, White RL. Evaluation of the Cost of Antibiotic Therapy in Penetrating Abdominal Trauma. 23rd Annual Midyear Meeting of the American Society of Hospital Pharmacists. Dallas, Texas. December 6, 1988. (Abstract #P141).

Fuhrman BL, White RL, Brundage R, Twitty JA. Effect of Piperacillin vs. Amikacin on Bactericidal Activity and Initial Kill Rate of Piperacillin/Amikacin Combinations. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Los Angeles, California. October 24, 1988. (Abstract #85).

White RL, Yost R, Kays MB, Bednarczyk E. Clindamycin serum protein binding in subjects with variable alpha-1-acid glycoprotein concentrations. 9th Annual Meeting of the American College of Clinical Pharmacy. Philadelphia, Pennsylvania, July 24, 1988. (Abstract #47).

White R, Bannister E, and Scott L. Quantitation of the "skipped well" phenomenon in broth microdilution MBC testing. The 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. New York, New York. October 5, 1987 (Abstract #334).

Hooker KD and White, RL. Microbiologic and pharmacodynamic evaluation of aztreonam. The 8th Annual Meeting of the American College of Clinical Pharmacy. Austin, Texas. July 21, 1987. (Abstract #21).

Marchbanks CR, White RL, Yost RL. Cefotaxime stability during in vitro microbiological testing. The 8th Annual Meeting of the American College of Clinical Pharmacy. Austin, Texas. July 21, 1987. (Abstract #50).

White RL, Nightingale CH, Quintiliani R. Serum and uterine tissue concentrations of cefoxitin and cefotaxime in

women undergoing hysterectomy. 15th International Congress of Chemotherapy. Istanbul, Turkey. July 1987.

White RL, Marchbanks CR, Yost RL. Antibiotic stability during microbiological testing. 3rd European Congress of Clinical Microbiology. The Hague, The Netherlands, May 12, 1987.

Bachmann L, White R, Jozefczyk K, Robinson M. A study of the stability of commercially prepared antibiotics in Viaflex Plus<sup>R</sup> bags. 44th Annual Meeting of the American Society of Hospital Pharmacists. Washington, D.C. June 2, 1987.

White RL, Nightingale CH, Quintiliani R. The crossover pharmacokinetics and pharmacodynamics of ceftriaxone, ceftizoxime and cefoperazone in healthy volunteers. The 26th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, Louisiana. September 30, 1986. (Abstract #583)

White RL, Nightingale CH, Quintiliani R, Tress J. The pharmacokinetics of cefuroxime and cefamandole in healthy volunteers. The 6th Annual Meeting of the American College of Clinical Pharmacy. Orlando, Florida. July 8, 1985. (Abstract #79).

Nightingale CH, White RL, Quintiliani R. The cost-effective use of imipenem/cilastatin in the hospital setting. International Congress of Chemotherapy. Kyoto, Japan. June, 1985.

White RL, Nightingale CH, Quintiliani R, Hickingbotham M, Whitaker KF, Jones III RF, Tripp WH. Cefoxitin and cefotaxime in gynecological procedures: Comparative pharmacokinetics in serum and uterus. The 86th annual meeting of the American Society for Clinical Pharmacology and Therapeutics. San Antonio, Texas. March 30, 1985. (Abstract #C-15).

White RL, Garnett WR, Poynor WG, et al. Quantitation of salicylate removal during plasma exchange in normal volunteers. American Society of Hospital Pharmacists 18th Annual Midyear Clinical Meeting, Atlanta, Georgia. December 1983 (Abstract #CR-14).

White RL, Garnett WR, Allen JH, et al. Removal of phenytoin during plasma exchange. American Society of Hospital Pharmacists 17th Annual Midyear Clinical Meeting. Los Angeles, California. (Abstract #P-224).

### **CURRENT RESEARCH FUNDING**

Role of Surfactant Protein B in Innate Airway Defense (NIH 1R01HL066066-01; 7-1-01 through 6-30-05; 10% salary effort)

Comparison of pharmacodynamic activity of gatifloxacin and levofloxacin against *Streptococcus pneumoniae* using Monte Carlo Analysis, Co-principal investigator, 2001- (funded – Bristol-Myers Squibb; \$28,191).

Assessment of susceptibility of *Streptococcus pneumoniae* to fluoroquinolones, Co-principal investigator, 2001-2 (funded – Bristol-Myers Squibb; \$8,000).

Assessment of susceptibility trends in *Streptococcus pneumoniae* to macrolide and ketolide antibiotics, Co-principal investigator, 2002 – (funded – Aventis; \$23,351).

Evaluation of the effects of changing renal function as they relate to labeled and theoretical dosing adjustments on the pharmacodynamics and pharmoeconomics of fluoroquinolone therapy. (principal investigator, funded 2000, Bayer \$14,500)

Comparative pharmacodynamics of newer fluoroquinolones. (principal investigator, funded 2000, Bristol-Myers Squibb \$10,000)

Pilot study for the South Carolina antimicrobial use and resistance surveillance network. (co-principal investigator, funded 2000, Bristol-Myers Squibb \$7,500 and Bayer \$3,000)

Impact of zinc concentrations on the microbiologic activity of carbapenems (principal investigator, funded 1999, Merck \$25,000)

### **OTHER FUNDING**

Infectious Diseases Pharmacotherapy CE Program – 2002, Co-principal investigator, 2002 (funded – Pharmacia; \$32,000).

Infectious Diseases Pharmacotherapy Workshop – 2002 Co-principal investigator, 2002 (funded – Bayer; \$25,000).

Residents' Infectious Diseases Pharmacotherapy Workshop, Co-principal investigator, 2002 (funded – Ortho-McNeil; \$15,000).

Pharmacia Anti-infective Group Training Program. Co-principal investigator, 2001 (funded-Pharmacia; \$5,000)

In vitro model training program for Abbott Laboratories Research Scientist. Co-principal investigator, 2002 (funded Abbott; \$8,600)

### **INVITED PRESENTATIONS**

Update on antibiotics. MUSC Family Practice Symposium. Charleston, SC. May 23, 2002

Use of susceptibility data in antimicrobial decision-making. Clinical Microbiology Laboratory, MUSC. Charleston, SC. May 16, 2002

Current concepts in the pathophysiology and pharmacotherapy of viral hepatitis. Making a Difference Conference. Orlando, FL. May 5, 2002

Laboratory diagnostics/susceptibility testing Workshops. Making a Difference Conference. Orlando, FL. May 2, 2002.

Antimicrobial resistance in respiratory tract infections and antimicrobial pharmacodynamics: implications for the selection of therapy. Making a Difference Conference. Orlando, FL. May 2, 2002

Internet Resources in Infectious Diseases. MUSC Anti-infective Workshop. Charleston, SC. April 27, 2002.

Update on new antimicrobials. MUSC Anti-infective Workshop. Charleston, SC. April 27, 2002.

Pharmacokinetics and pharmacodynamics of ertapenem. Merck Infectious Diseases/Clinical Pharmacy Program. Scottsdale, AZ. March 8, 2002.

Antibiotic Selection in the ICU. Spartanburg Regional Medical Center. Spartanburg, SC. February 12, 2002.

Local and national resistance surveillance. Pharmacia Anti-infective Training Program. Charleston, SC. December 13, 2001

Evaluation of in vitro microbiological activity. Pharmacia Anti-infective Training Program. Charleston, SC. December 13, 2001

What in vitro models can and cannot do. Abbott Anti-infectives Research Group. Chicago, IL. December 5, 2001.

NCCAP Carolina Seminar. Update on Antimicrobial Resistance. Greensboro, NC. October 29, 2001

Therapeutic Update: Pharmacodynamics, Antibiotic Cycling. Presented at Regional Anti-Infective Workshops in Charlotte, NC (October 6, 2001) San Diego, CA (October 16, 2001), Baltimore, MD (October 31, 2001), and Detroit, MI (November 5, 2001)

Application of Susceptibility and Surveillance Data. Presented at Regional Anti-Infective Workshops in Charlotte, NC (October 6, 2001) San Diego, CA (October 16, 2001), Baltimore, MD (October 31, 2001), and Detroit, MI (November 5, 2001)

Formulary evaluation of New Antimicrobials. Presented at Regional Anti-Infective Workshops in Charlotte, NC (October 6, 2001) San Diego, CA (October 16, 2001), Baltimore, MD (October 31, 2001), and Detroit, MI (November 5, 2001)

What in vitro models can and cannot do. American College of Clinical Pharmacy Annual Meeting. Tampa, FL. October 23, 2001

Pharmacodynamics of Antimicrobials. Orlando Regional Medical Center. Orlando, FL. September 11, 2001

Current issues with novel therapies and the development of antibiotic resistance. National Pharmacy Consultants Meeting. Vancouver, British Columbia, Canada. August 3, 2001.

Antimicrobial Resistance. Savannah Memorial Hospital. Savannah, GA. July 27, 2001

Formulary evaluation of new antimicrobials. 4<sup>th</sup> Annual Medical University of South Carolina Residents' Workshop Charleston, SC. July 6, 2001.

Antimicrobial pharmacodynamics. 4<sup>th</sup> Annual Medical University of South Carolina Residents' Workshop. Charleston, SC. July 6, 2001.

Update on antifungal susceptibility testing. 4<sup>th</sup> Annual Medical University of South Carolina Residents' Workshop. Charleston, SC. July 6, 2001.

Evaluation of in vitro microbiologic activity/ antibiogram exercise. 4<sup>th</sup> Annual Medical University of South Carolina Residents' Workshop. Charleston, SC. July 6, 2001.

Factors in the selection of antimicrobials. 5<sup>th</sup> Annual Medical University of South Carolina Infectious Diseases Workshop. Charleston, SC. May 12, 2001.

Indications for combinations of antimicrobials. 5<sup>th</sup> Annual Medical University of South Carolina Infectious Diseases Workshop. Charleston, SC. May 12, 2001.

Use of susceptibility data in individual patients and in populations of patients. 5<sup>th</sup> Annual Medical University of South Carolina Infectious Diseases Workshop. Charleston, SC. May 12, 2001.

Update on pharmacodynamics. 5<sup>th</sup> Annual Medical University of South Carolina Infectious Diseases Workshop. Charleston, SC. May 12, 2001.

Formulary considerations with carbapenems. Parkland Hospital Grand Rounds. Dallas, TX. April 6, 2001.

Treatment of gram-negative bacilli infections in the ICU. University of Texas Infectious Diseases Symposium. San Antonio, TX. March 24, 2001.

Antimicrobial pharmacodynamics. Abbott Anti-Infective Consultants Meeting. Charlotte, NC. March 3, 2001.

Treatment of gram-negative infections. Ortho-McNeil Pharmacy Symposium. Charleston, SC. January 27, 2001.

Informatics based antimicrobial management. NC Antimicrobial Stewardship Effort Meeting. Greensboro, NC. December 9, 2000.

Factors in the selection of antimicrobials. Symposium on Antimicrobial Resistance at American Society of Health Systems Pharmacists Midyear Meeting. Las Vegas, NV. December 4, 2000.

Antimicrobial cycling. Duke University Grand Rounds. Durham, NC. November 30, 2000.

What in vitro models can and cannot do. Symposium on Antimicrobial Pharmacodynamics at American College of Clinical Pharmacy. Los Angeles, CA. November 7, 2000.

Do advances in hepatitis C treatment improve outcomes? American College of Clinical Pharmacy Annual Meeting. Los Angeles, CA. November 6, 2000.

Role of ketolides. Symposium on Maximizing Outcomes in Respiratory Infections at American College of Clinical Pharmacy Annual Meeting. Los Angeles, CA. November 5, 2000.

Update on fluoroquinolones. Horry County Medical Society. Myrtle Beach, SC. October 24, 2000.

Clinical use of susceptibility data. Bayer Regional Workshops in Seattle, WA.(September 13, 2000), Tampa, FL. (October 11, 2000), Phoenix, AZ. (October 21, 2000), Los Angeles, CA. (November 9, 2000), and Boston, MA. (November 15, 2000).

Formulary selection of antimicrobials. Bayer Regional Workshops in Seattle, WA.(September 13, 2000), Tampa, FL. (October 11, 2000), Phoenix, AZ. (October 21, 2000), Los Angeles, CA. (November 9, 2000), and Boston, MA. (November 15, 2000).

Antimicrobial pharmacodynamics. Bayer Regional Workshops in Seattle, WA.(September 13, 2000), Tampa, FL. (October 11, 2000), Phoenix, AZ. (October 21, 2000), Los Angeles, CA. (November 9, 2000), and Boston, MA. (November 15, 2000).

Selection of antimicrobials and relevant laboratory evaluations. Searle Medical Affairs Managers. Chicago, IL. October 5, 2000.

Clinical use of susceptibility data. Medical College of Georgia Grand Rounds. Augusta, GA. October 4, 2000.

Antimicrobial pharmacokinetics and pharmacodynamics. SC Pharmacy Association 3<sup>rd</sup> District. September 11, 2000.

Antimicrobial cycling. Massachusetts General Hospital Grand Rounds. Boston, MA. August 31, 2000.

Selection of antimicrobials. Massachusetts General Hospital Grand Rounds. Boston, MA. August 31, 2000.

Antimicrobial pharmacodynamics. Bayer Regional Workshop. Washington, DC. August 3, 2000.

Formulary selection of antimicrobials. Bayer Regional Workshop. Washington, DC. August 3, 2000.

Clinical use of susceptibility data. Bayer Regional Workshop. Washington, DC. August 3, 2000.

Update on Telithromycin. Charleston, SC. July 22, 2000.

Update on Telithromycin. Atlantic City, NJ. July 15, 2000.

In vitro susceptibility testing. Medical University of South Carolina Pharmacy Residents' Workshop, Charleston, SC. July 7, 2000.

Antimicrobial pharmacodynamics. Medical University of South Carolina Pharmacy Residents' Workshop, Charleston, SC. July 7, 2000.

Once daily aminoglycosides. Medical University of South Carolina Pharmacy Residents' Workshop, Charleston, SC. July 7, 2000.

Factors in antimicrobial selection. Medical University of South Carolina Pharmacy Residents' Workshop,

Charleston, SC. July 7, 2000.

Update on Hepatitis C. American College of Clinical Pharmacists Spring Research and Practice Forum. Monterey, CA. April 5, 2000.

What in vitro pharmacodynamic models can't do. Annual Infectious Diseases Pharmacotherapy Fellowship Forum. Hilton Head Island, SC. March 23, 2000.

Fluoroquinolones in the treatment of respiratory tract infections. Kershaw County Medical Society. Camden, SC. March 6, 2000.

Quantitative relationships between antibiotic use and resistance: are we measuring the right things? SCOPE Symposium 2000. Atlanta, GA. March 3, 2000.

Use of high-dose fluconazole. Charleston, SC. February 29, 2000.

Use of high-dose fluconazole. VA Hospital. Tampa, FL. December 6, 1999.

Clinical Application of Pharmacodynamic Principles. Richland Memorial Hospital Pharmacy Grand Rounds. January 26, 1999.

Pitfalls in the evaluation of antimicrobial usage vs susceptibility data. VCU/MCV Pharmacy Grand Rounds, November 16, 1998

Visiting Professor Lecture on Antimicrobial Pharmacodynamics. Candler and St. Josephs Hospitals pharmacy and medical staffs. April 23, 1998.

Anti-infective pharmacodynamics: the host, organism, drug interface. American College of Clinical Pharmacy Spring Practice and Research Forum. April 6, 1998. Palm Springs, CA.

Evaluation of the relationship between antimicrobial usage vs. susceptibility: Lessons learned. Management of serious infections in hospitalized patients: the impact of antimicrobial resistance symposium. American Society of Health Systems Pharmacists Midyear Clinical Meeting. Atlanta, Georgia. December 9, 1997.

Zithromax IV - Roundtable focus group discussion. American Society of Health System Pharmacists Midyear Clinical Meeting. Atlanta, Georgia. December 7, 1997.

Update on antibiotics 1998 - Antimicrobial resistance and the impact of antibiotic usage. Quorum Health Group, Inc. Atlanta, Georgia. December 6, 1997.

Should antimicrobials be cycled to influence the antibiogram? American College of Clinical Pharmacy Annual Meeting, Phoenix Arizona, Phoenix, Arizona. November 11, 1997.

Update on the treatment of hepatitis. Durham-Orange Pharmaceutical Association, Durham, North Carolina. October 15, 1997.

Strategies for formulary considerations of new anti-infective agents. Infectious Diseases Pharmacotherapy Symposium, Charleston, South Carolina. September 26, 1997.

Pharmacotherapy of infections with resistant gram-negative organisms. Baptist Hospital Department of Pharmacy, Winston-Salem, North Carolina. July 16, 1997.

Issues in the formulary selection of carbapenems. Alliance Hospital Group. Atlanta, Georgia. February 18, 1997.

Pharmacodynamics of antimicrobials. Symposium on Contemporary Hospital Infections: therapeutic considerations and formulary management. American Society of Health Systems Pharmacists Midyear Clinical Meeting. New Orleans, Louisiana. December 9, 1996.

Pitfalls in the evaluation of the relationship between antimicrobial use and bacterial resistance. University of Kentucky Pharmacy residents conference. Lexington, Kentucky. November 20, 1996.

Formulary issues in an era of gram-negative bacterial resistance. Lexington area hospital pharmacists. Lexington, Kentucky. November 19, 1996.

Issues in Tissue Penetration with the Macrolides. Charleston Area Housestaff. Charleston, SC. March 15, 1996.

Clinical Pearls in Infectious Diseases: The Serum Bactericidal Titer Test. 30th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 5, 1995.

Therapeutic Debates: Once Daily Aminoglycosides. 30th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 4, 1995.

Update on Newer Antimicrobials. Lowcountry AHEC. November 19, 1995. Charleston, S.C.

New Strategies in Antimicrobial Dosing. Baptist Hospital Grand Rounds. Winston-Salem, NC. October 6, 1995.

Application of Pharmacologic Principles in Designing Antimicrobial Dosing Regimens. ASHP Annual Meeting. June 8, 1995. Philadelphia, PA.

Antimicrobial Pharmacodynamics. Duke University Department of Pharmacy Grand Rounds. October 11, 1994. Durham, NC

Antimicrobial Selection: What the Pharmacist Needs to Know. New England Council of Hospital Pharmacists Fall Seminar. November 3, 1994. Providence, RI

Current Issues in Infectious Diseases Research. Hartford Hospital Infectious Disease Research Group. November 2, 1994. Hartford, CT

Outpatient Treatment of Pneumonia. Pharmacotherapeutics for Advanced Practice Nursing. College of Nursing. MUSC. October 18, 1994. Charleston, SC

Antibiotic Cost Containment. Pharmacotherapeutics for Advanced Practice Nursing. College of Nursing. MUSC. October 19, 1994. Charleston, SC

Formulary Decisions-1994. Infectious Disease Pharmacotherapy Symposium. College of Pharmacy. MUSC. September 23, 1994. Charleston, SC

Application of pharmacokinetic and pharmacodynamic principles in designing antimicrobial dosage regimens. California Society of Hospital Pharmacists Annual Meeting. San Francisco, California, October 30, 1993

Overview of antimicrobial research at MUSC. University of California at San Francisco. San Francisco, California, October 29, 1993.

Use of pharmacodynamic equations to establish initial interpretive guidelines. International Society of Anti-Infective Pharmacology Annual Meeting. New Orleans, Louisiana, October 20, 1993.

Clinical use of antimicrobials. Pharmacotherapeutics for Nurse Midwives and Adult Primary Care Practitioners. Medical University of South Carolina College of Nursing. Charleston, South Carolina, September 23, 1993.

Antimicrobial Pharmacodynamics: Potential use in the Design of Antimicrobial Regimens in Specific Patients. Medical University of South Carolina, Faculty Seminar Series, September 16, 1993.

Monoclonal Antibodies and Therapeutics. Association of Faculties of Pharmacy of Canada, Pharmaceutical Biotechnology Conference, Vancouver, British Columbia, Canada, August 3, 1993.

Genito-Urinary Disorders: Urinary Tract Infections. Pharmacotherapeutics for Nurse Midwives and Adult Primary Care Practitioners. Medical University of South Carolina College of Nursing. Charleston, South Carolina. March 2, 1993.

Chemistry and Therapeutic Scenarios (CATS). Sponsored by the American Association of Colleges of Pharmacy. Taped in Omaha, Nebraska. February 20, 1993.

Dosing considerations in antimicrobial chemotherapy. New Horizons in Antimicrobial Therapy, Richmond, Virginia. October 30, 1992.

Antimicrobial adverse reactions and drug interactions. Sumter County Medical Society, Sumter, South Carolina. November 5, 1992.

Antibiotic Selection in the 1990's. Eastern Area Health Education Center Symposium. Wrightsville Beach, NC. July 25, 1992.

Effective Communication in Professional Instruction. American Association of Colleges of Pharmacy 93rd Annual Meeting. Washington, D.C. July 15, 1992.

Macrolides: Past, Present and Future. Arkansas Society of Hospital Pharmacists Annual Meeting. Little Rock, Arkansas. June 19, 1992.

Macrolides: Past, Present and Future. Northern Hospital of Surry County. Mt. Airy, North Carolina. May 3, 1992.

Macrolides: Past, Present and Future. Virginia Society of Hospital Pharmacists. Norfolk, Virginia. March 16, 1992.

Issues in the Selection of Antimicrobials. Pharmacy and Therapeutics Committee, Northlake Medical Center. Atlanta, Georgia. March 11, 1992.

New Developments in Antimicrobial Identification and Susceptibility Testing. Updates in Pharmacotherapy: Infectious Diseases. American College of Clinical Pharmacy 1992 Winter Practice and Research Forum. Phoenix, Arizona. February 12, 1992.

Formulary Issues with Antianaerobic Beta-Lactams. Medical Grand Rounds. Sentara Bayside Hospital. Virginia Beach, Virginia. December 19, 1991

Pitfalls in the Interpretation of Susceptibility Results. Pharmacy Discussion Group. Medical University of South Carolina. Charleston, South Carolina. December 3, 1991.

Macrolides: Past, Present, and Future. Canadian Society of Hospital Pharmacists - British Columbia Branch Annual Meeting. Vancouver, Canada. November 16, 1991.

Clinical use of the Fluoroquinolones. Family Practice Group. Martin Army Community Hospital. Columbus, Georgia. October 24, 1991.

Issues in the Formulary Selection of Cephalosporins. West Georgia Medical Society. La Grange, Georgia. October 24, 1991.

Controversies in the Selection of Third-Generation Cephalosporins. Eastern Coastal Pharmaceutical Society. Daytona Beach, Florida. October 3, 1991.

Controversies in the Selection of Third-Generation Cephalosporins. Broward County Pharmacy Association. Ft. Lauderdale, Florida. September 11, 1991

The Use of Cephalosporins in Treatment of Antianaerobic Infections. Knoxville Area Hospital Pharmacists Association. Knoxville, Tennessee. September 10, 1991.

Update on Cephalosporins. Pharmacy Staff. Roper Hospital. Charleston, South Carolina August 8, 1991.

The Importance of Medicinal Chemistry in Clinical Practice. Section of Teachers of Chemistry. American Association of Colleges of Pharmacy 92nd Annual Meeting. Boston, Massachusetts. July 10, 1991.

The Sepsis Syndrome: Clinical Picture and Current Practice on program entitled Monoclonal Antibody Technology - Update for the Pharmacist. Medical University of South Carolina, Charleston, SC. June 11, 1991.

Formulary Evaluation of Cephalosporins. Pharmacy Staff. Lankenau Hospital. Philadelphia, Pennsylvania. May 1, 1991.

Pharmacodynamics of Antimicrobials. Pharmacy Staffs of Wesley Long and Moses Cone Hospitals. Greensboro, North Carolina. March 15, 1991.

Formulary Evaluation of Antimicrobials. Family Practice Group. Navy Hospital. Charleston, South Carolina. March 14, 1991.

Evaluation of Cephalosporins with Anti-Anaerobic Activity. Southeastern Florida Pharmaceutical Association. Ft. Lauderdale, Florida, January 21, 1991.

Issues in the Formulary Selection of Antimicrobials Pharmacy Staff. Catawba Memorial Hospital Pharmacy Department. Hickory, North Carolina. November 14, 1990.

Evaluation of Antifungals. AIDS Treatment Center. Jackson Memorial Hospital. Miami, Florida. November 2, 1990.

The Fluoroquinolones: Clinical Evaluation of Current and Future Agents. Medical Grand Rounds. Mullins Hospital. Mullins, South Carolina. October 8, 1990.

Treatment of Fungal Infections-Update on New Treatment Options. Virginia Society of Hospital Pharmacists. Region III. Roanoke, Virginia. September 30, 1990.

Cephalosporins with Activity Against Anaerobes - Formulary Considerations. Pharmacy Staffs of Emory, Baptist and Northside Hospitals. Atlanta, Georgia. September 27, 1990.

Update on Drug Interactions Involving Antimicrobials. Internal Medicine Grand Rounds. Greenville Memorial Hospital. Greenville, South Carolina. September 14, 1990.

Adverse Reactions to Antimicrobials. Pharmacy Staffs of Greenville Memorial and St. Francis Hospitals. Greenville, South Carolina. September 13, 1990.

Update on Antifungals. Live Telenet Conference from Medical University of South Carolina. September 11, 1990.

Aztreonam: Clinical Uses in Combination Therapy. Pharmacy Staff. Emory and Eggleston Hospitals. Atlanta, Georgia. July 9, 1990.

Third Generation Cephalosporins Revisited. Henderson Obstetrics and Gynecology Group. Henderson, North Carolina. June 21, 1990.

Cephalosporins: Issues in Formulary Decisions. Pharmacy Staff. McLeod Regional Medical Center. Florence, South Carolina. June 19, 1990.

Therapy of Anaerobic Infections. Obstetrics/Gynecology Grand Rounds. Richland Memorial Hospital. Columbia, South Carolina. June 19, 1990.

Pharmacodynamics of Antimicrobials. Medical Staff Medical Center. Columbus, Georgia. May 9, 1990.

In Vitro Evaluation of Antimicrobials. Symposium on Therapeutic Issues in Cardiovascular and Infectious Diseases. Charleston, South Carolina. April 27, 1990.

In Vitro Evaluation of Antimicrobials. Symposium on Therapeutic Issues in Cardiovascular and Infectious Diseases. Richmond, Virginia. April 26, 1990.

Pharmacodynamic Analysis of Cephalosporins with Anti-Anaerobic Activity. Symposium on Management of Mixed Infections. Charleston, South Carolina. April 14, 1990.

Update on Oral Antimicrobials. Family Practice Grand Rounds. Charlotte Memorial Hospital. Charlotte, North Carolina. April 11, 1990.

The Use of In Vitro Microbiologic Data in Antibiotic Decision-making. Pharmacy Staff. Richland Memorial Hospital, Columbia, South Carolina. April 9, 1990.

Update on Cephalosporins. Pharmacy Staff. Baptist Hospital. Winston-Salem, North Carolina. April 5, 1990.

Third-generation Cephalosporins. Minnesota Society of Hospital Pharmacists Annual Meeting. Minneapolis, Minnesota. March 30, 1990.

Fluoroquinolones: Current Use and Future Considerations. Minnesota Society of Hospital Pharmacists Annual Meeting. Minneapolis, Minnesota. March 30, 1990.

Cephalosporins: Issues in Formulary Decisions. Medicine/Surgery Grand Rounds. Cleveland County Memorial Hospital. Shelby, North Carolina. February 20, 1990.

Pharmacodynamics of Beta-Lactam Antimicrobials. Pharmacy Staff. Mercy and Presbyterian Hospitals. Charlotte, North Carolina. February 19, 1990.

Update on Susceptibility Testing. Family Practice Grand Rounds. Anderson Memorial Hospital. Anderson, South Carolina. February 13, 1990.

Formulary Considerations with Cephalosporins. Orlando Regional Pharmacists. Orlando, Florida. December 12, 1989.

Antimicrobial Therapy of Mixed Aerobic-Anaerobic Infections. Family Practice Grand Rounds. Portsmouth Family Practice Center. Portsmouth, Virginia. December 8, 1989.

Use of Microbiologic Data in Formulary Decisions. Surgical Staff, Savannah Memorial Hospital. Savannah, GA October 25, 1989.

Antimicrobial Drug Interactions. South Carolina Pharmaceutical Association (13th district). Greenville, South Carolina. October 10, 1989.

Community-Acquired Pneumonias. 23rd Hospital and 15th Clinical Annual Carolina Seminar. North Carolina Society of Hospital Pharmacists. Greensboro, NC September 21, 1989.

Pharmacodynamics of Cephalosporins. MUSC Surgical Staff. Charleston, SC September 7, 1989.

Pharmacodynamic Evaluation of the Activity of Cephalosporins Against Anaerobic Organisms. Surgical House Staff - Medical University of South Carolina. Charleston, SC September 7, 1989.

The Fluoroquinolones. East Cooper Family Practice Group. East Cooper Hospital. Mt. Pleasant, SC. July 27, 1989

Formulary Evaluation of Cephalosporins. The Pharmacy Staff, Medical Center. Columbus, GA. July 18, 1989.  
Use of Cephalosporins in Anaerobic Infections. Obstetrics/Gynecology Grand Rounds. Medical Center. Columbus, GA. July 18, 1989.

Update on Drug Interactions Involving Antimicrobials. Piedmont Pharmaceutical Association. Spartanburg, South Carolina. May 23, 1989.

The Use of Susceptibility Testing in Antibiotic Selection. Medical Grand Rounds. Richland Memorial Hospital. Columbia, South Carolina. March 22, 1989.

Clinical Use of the Fluoroquinolones. Medical Staff - Medical University of South Carolina. Charleston, South Carolina. March 15, 1989.

Antimicrobial Pharmacodynamics. Family Practice Grand Rounds. Spartanburg Regional Medical Center, Spartanburg, South Carolina. January 18, 1989.

Use of Microbiologic Data in Antibiotic Decision Making. Pharmacy Focus Symposium. Charleston, South Carolina. November 12, 1988.

Ensuring Rational Antibiotic Use by Integrating Therapeutic and Fiscal Considerations. Florida Society of Hospital Pharmacists 22nd Annual Meeting. Orlando, Florida. September 17, 1988.

Pharmacodynamics of Aminoglycosides. Medical Staff - Medical University of South Carolina. Charleston, South Carolina. August 15, 1988.

New Antimicrobials on the Horizon. HPI Health Care Services Antibiotic Symposium. Orlando, Florida. March 18, 1988.

The Fluoroquinolones. APhA Annual Meeting. Atlanta, Georgia. March 15, 1988.

Update on Antimicrobial Drugs. Mountain Area Health Education Center. Asheville, North Carolina. October 11, 1987.

Aminoglycoside Pharmacodynamic Ratio Analysis. Eli Lilly Co. Indianapolis, Indiana. August 7, 1987.

Clinical indications for antibiotics in the outpatient setting. Connecticut Pharmaceutical Association. Meriden, Connecticut. February 13, 1985.

Basic Pharmacokinetic Principles. Pharmacy Staff - King's Daughter's Children's Hospital. Norfolk, Virginia. November 17, 1982.

Clinical Pharmacokinetics Service. Presented at press conference. Louise Obici Memorial Hospital. Suffolk, Virginia.

Advances in Chemotherapy. Lenoir County Hospital. Kinston, North Carolina. March 18, 1981.

Update on New Drugs. Catawba Technical Institute. Hickory, North Carolina. Accredited Nursing Continuing Education Program. September 16, 1979.

## **WORKSHOPS**

Annual MUSC Anti-Infective Workshops for Pharmacists in South Carolina: 1997-2002  
(coordinator and presenter)

Annual Anti-Infective Workshops for Pharmacy Residents: 1998 -2001  
(coordinator and presenter)

## **VIDEOTAPE PRESENTATIONS**

Chemistry and Therapeutic Scenarios (CATS). Sponsored by the American Association of Colleges of Pharmacy. Taped in Omaha, Nebraska. February 20, 1993.

Live Satellite Symposium on Monoclonal Antibody Technology. Medical University of South Carolina, Charleston, SC. June 11, 1991.

Proactive Intervention: Converting Patients from IV to Oral Antibiotics (Panel Discussant). Health Communications Network. Charleston, South Carolina. December 12, 1990.

Update on Antifungals: Clinical Evaluation and Formulary Considerations. Grady Hospital Pharmacy Grand Rounds. Atlanta, Georgia. July 10, 1990.

### **EDITORIAL BOARD MEMBERSHIP**

Journal of Infectious Disease Pharmacotherapy  
Antimicrobics and Infectious Diseases Newsletter, Senior Editor  
Pharmacotherapy 1993-96

### **CONSULTING**

Advisory Boards for Abbott, AstraZeneca, Bayer, Bristol-Myers Squibb, Merck, Pharmacia

### **RESIDENCY PRECEPTORSHIP**

K. Dale Hooker, Pharm.D., 1986-87  
Michael B. Kays, Pharm.D., 1988-89

### **FELLOWSHIP PRECEPTORSHIP**

Kevin Enzweiler, Pharm.D. 2000-2002  
Charles Bonapace, Pharm.D., 1997-2000  
Linda Mihm, Pharm.D. 1995-1997  
Madhavi Manduru, Pharm.D. 1994-1996  
David S. Burgess, Pharm.D., 1991 - 1994  
Lawrence V. Friedrich, Pharm.D., 1988 - 1991  
Michael B. Kays, Pharm.D., 1989 - 1991

### **REVIEWER**

Antimicrobial Agents and Chemotherapy  
Pharmacotherapy  
Annals of Pharmacotherapy

### **PROFESSIONAL EXPERIENCE**

Medical College of Virginia Hospitals  
Richmond, Virginia - Staff pharmacist  
September 1981 - May 1983

Pitt County Memorial Hospital  
Greenville, North Carolina - Staff pharmacist  
November 1979 - August 1981

Gordon Crowell Memorial Hospital  
Lincolnton, North Carolina - Pharmacy intern  
June 1979 - October 1979

### **HONORS**

American College of Clinical Pharmacy-Preceptor for Ortho Infectious Disease Research Fellowship 1996-7

Elected Fellow, American College of Clinical Pharmacy, 1994

Health Sciences Foundation Developing Scholar Award  
Medical University of South Carolina, 1992

Preceptor of the Year, MUSC Doctor of Pharmacy Program, 1993-94 and 1996-97

Professor of the Year, Medical University of South Carolina, Doctor of Pharmacy Class of 1990

Medical College of Virginia, Rho Chi Honor Society, 1982

University of North Carolina at Chapel Hill, Deans List, 1978 - 1979

### **COMMITTEE MEMBERSHIP**

#### **Current:**

Departmental: Task Force on Development of a PharmD/PhD Program  
Promotion and Tenure Committee, January 1989 - present

College: Appointments, Promotions, and Tenure Committee, 2001-present  
Graduate committee for Carsten Fischer, PhD candidate

University: University Tenure Committee 2001-present  
Appletree Society, January 1999-present

### **COMMITTEE MEMBERSHIP (continued)**

#### **Past:**

##### Medical University of South Carolina

Committee on Educational Technology, November 1996 - 2000  
College of Pharmacy Admissions Committee, January 1995 - 2001  
College of Pharmacy Research and Graduate Studies Committee, October 1986 - 2001  
Graduate Committee for Shuiyang Yu - Candidate for Ph.D. in Biostatistics, 1994  
Research Faculty Liaison Committee, January 1990 - December 1994  
Residency Committee, October 1987 - January 1989  
Pharmacy and Therapeutics Committee, January 1987 - January 1993  
Antibiotic Subcommittee 1987 - 1998, , Secretary 1987-1993, Chair 1993-1998  
College of Pharmacy Curriculum Committee 2000  
College of Pharmacy Self-Study Committee on Faculty 1998-1999  
College of Pharmacy Search Committee (Pharmacoeconomics/Pharmacoepidemiology) 1998-pres.  
Doctor of Pharmacy Curriculum Committee, January 1986 - January 1987

### **PROFESSIONAL ORGANIZATIONS**

#### **Current:**

Society of Infectious Diseases Pharmacists, 1991 – present

American College of Clinical Pharmacy, 1984 – present  
Grants Selection Committee, 2001-present

American Society of Microbiology, 1986 – present

Infectious Diseases Society of America, 2001-present  
Antibiotic Use and Clinical Trials Committee, 2001-present

American Association of Colleges of Pharmacy, 1986 - present

**Past:**

Society of Infectious Diseases Pharmacists  
Secretary-Treasurer and Board of Directors, 1996-1998  
Membership Committee, 1991 -1993, Chair, 1993

American College of Clinical Pharmacy  
Fellowship Review Committee, 1997-1999  
Educational Affairs Committee 1995-96  
Research Affairs Committee, 1990-91  
Planning Committee, 1986-87

American Association of Colleges of Pharmacy  
Awards Committee, 1990-91

American Society of Hospital Pharmacists, 1979 - 1994  
Infectious Diseases Specialty Practice Group, 1990 - 1993